论文部分内容阅读
在一项开放研究中评价了氟罗沙星(F-leroxacin)在12例建康男性志愿者,6例肝硬化无腹水(A组)、6例肝硬化腹水(B组)患者一的处置情况。受试者年龄30～68岁,体重为标准体重±20%,均在给药前5d禁用其它药物。采用随机交叉设计,第一天单剂量口服安替比林500mg考察肝微粒体酶的活性,在第8d和第15d分别单剂量口服和静滴(60min滴完)氟罗沙星400mg,于不同时间收集血液和尿液,用HPLC测定氟罗沙星及其代谢产物(N-去甲氟罗沙星、N-氧化氟罗沙星)浓度。结果在三组试验者中,氟罗沙星均完
In an open-label study, treatment of flea F-lexacin in 12 male patients with Jiankang, 6 patients with cirrhosis without ascites (group A), and 6 patients with cirrhosis of the liver (group B) was evaluated. Subjects aged 30 to 68 years old, body weight of standard weight ± 20%, were banned 5d before the other drugs. A randomized crossover design was adopted. On the first day, a single oral dose of antipyrine 500 mg was used to investigate the activity of hepatic microsomal enzymes. A single oral dose of 400 mg of fleroxacin was administered orally and intravenously (60 min) on the 8th day and the 15th day respectively. Blood and urine were collected and the concentrations of fleroxacin and its metabolites (N-desfloxacin, fleroxanil N-oxide) were determined by HPLC. Results Among the three groups of participants, fleroxacin was completed